Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    Dapirolizumab Pegol

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus (PHOENYCS GO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04294667
Recruitment Status : Recruiting
First Posted : March 4, 2020
Last Update Posted : July 23, 2021
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma SRL )

Tracking Information
First Submitted Date  ICMJE February 27, 2020
First Posted Date  ICMJE March 4, 2020
Last Update Posted Date July 23, 2021
Actual Study Start Date  ICMJE August 12, 2020
Estimated Primary Completion Date February 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 2, 2020)
Achievement of BICLA response at Week 48 [ Time Frame: Week 48 ]
A study participant is considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following is fulfilled:
  1. British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
  2. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
  3. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as ≤10mm increase on a 100mm visual analog scale
Escape treatment intervention as indicated by Investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 14, 2021)
  • Achievement of BICLA response at Week 24 [ Time Frame: Week 24 ]
    A study participant is considered to be a BICLA responder if all of the following is fulfilled:
    1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
    2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
    3. No worsening in the PGA compared to Baseline Visit defined as ≤10mm increase on a 100mm visual analog scale
    Escape treatment intervention as indicated by Investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
  • Achievement of BICLA response at Week 12 [ Time Frame: Week 12 ]
    A study participant is considered to be a BICLA responder if all of the following is fulfilled:
    1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
    2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
    3. No worsening in the PGA compared to Baseline Visit defined as ≤10mm increase on a 100mm visual analog scale
    Escape treatment intervention as indicated by Investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
  • Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48 [ Time Frame: Week 48 ]
    BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
  • Achievement of LLDAS in ≥50% of post-Baseline visits through Week 48 [ Time Frame: Week 48 ]
    Low lupus disease activity state (LLDAS) is defined as:
    • No significant disease activity as per SLEDAI-2K and BILAG 2004 (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, fever)
    • No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit
    • PGA ≤33mm
    • Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5mg per day
    • Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
  • Change from Baseline in SLEDAI-2K at Week 48 [ Time Frame: From Baseline (Day 1) to Week 48 ]
    The SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K; 30 days) measures disease activity. It is a global index and includes 24 clinical symptoms and laboratory variables that are weighted by the type of manifestation, but not by severity or dynamic of the individual item. The total score falls between 0 and 105, with higher scores representing increased disease activity.
  • Achievement of BILAG improvement without worsening at Week 48 [ Time Frame: Week 48 ]
    The British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) grading is anchored in the physician's intention to treat. Disease activity is graded separately for 9 body systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, hematology) to 5 different grades (A to E) as follows: A ("Active") = Severely active disease B ("Beware") = Moderately active disease C ("Contentment") = Mild stable disease D ("Discount") = Inactive now but previously active E ("Excluded") = Never affected
  • Change from Baseline in PGA at Week 48 [ Time Frame: From Baseline (Day 1) to Week 48 ]
    Physician's Global Assessment of Disease (PGA) The Investigator will rate the overall status of the study participant in response to the following statement: "Please mark a vertical line on the scale below to assess the overall status of the study participant's Systemic Lupus Erythematosus signs and symptoms and the functional capacity of the study participant. The very far left end is 'very good, asymptomatic and no limitation of normal activities'; the very far right end indicates 'severe disease' . This refers to the most severe possible disease, and does not reflect the most severe ever seen in a particular patient, but the most severe disease ever seen in all SLE patients." When scoring the PGA, the assessor should always look back at the score from the previous visit.
  • Achievement of SRI4 response at Week 48 [ Time Frame: Week 48 ]
    The Systemic Lupus Erythematosus Responder Index (SRI)-4 define responders as (ie, all criteria must be met):
    • Reduction in SLEDAI-2K score of ≥4
    • No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline
    • No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline
    • No worsening in the PGA compared to study entry defined as ≤10mm increase on a 100mm visual analog scale
  • Achievement of prevention of moderate/severe BILAG flares (moderate/severe BILAG flare-free) through Week 48 [ Time Frame: Week 48 ]
    BILAG severe flare is defined as a new BILAG 2004 Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG- 2004 index (Yee et al, 2010)
  • Time to severe BILAG Flare through Week 48 [ Time Frame: During Treatment Period up to Week 48 ]
    BILAG severe flare is defined as a new BILAG 2004 Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
  • Time to moderate/severe BILAG flare through Week 48 [ Time Frame: During Treatment Period up to Week 48 ]
    BILAG severe flare is defined as a new BILAG 2004 Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG- 2004 index (Yee et al, 2010)
  • Percentage of participants with treatment-emergent adverse events (TEAEs) during the study [ Time Frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54) ]
    Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.
  • Percentage of participants with serious treatment-emergent adverse events during the study [ Time Frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54) ]
    A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose:
    • Results in death
    • Is life-threatening
    • Requires in patient hospitalisation or prolongation of existing hospitalisation
    • Is a congenital anomaly or birth defect
    • Is an infection that requires treatment with parenteral antibiotics
    • Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
  • Percentage of participants with treatment-emergent adverse events of special interest during the study [ Time Frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54) ]
    An adverse event of special interest is any AE that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound.
  • Percentage of participants with treatment-emergent adverse events of special monitoring during the study [ Time Frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54) ]
    An adverse event of special monitoring is a product-specific AEs, adverse reactions, or safety topics considered as requiring special monitoring by UCB.
Original Secondary Outcome Measures  ICMJE
 (submitted: March 2, 2020)
  • Achievement of BICLA response at Week 24 [ Time Frame: Week 24 ]
    A study participant is considered to be a BICLA responder if all of the following is fulfilled:
    1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
    2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
    3. No worsening in the PGA compared to Baseline Visit defined as ≤10mm increase on a 100mm visual analog scale
    Escape treatment intervention as indicated by Investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
  • Achievement of BICLA response at Week 12 [ Time Frame: Week 12 ]
    A study participant is considered to be a BICLA responder if all of the following is fulfilled:
    1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
    2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
    3. No worsening in the PGA compared to Baseline Visit defined as ≤10mm increase on a 100mm visual analog scale
    Escape treatment intervention as indicated by Investigator until the assessment time point will be defined as an intercurrent event for the primary endpoint leading to non-response from the day after the event onward.
  • Achievement of prevention of severe BILAG flares through Week 48 [ Time Frame: Week 48 ]
    BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
  • Achievement of LLDAS in ≥50% of post-Baseline visits through Week 48 [ Time Frame: Week 48 ]
    Low lupus disease activity state (LLDAS) is defined as:
    • No significant disease activity as per SLEDAI-2K and BILAG 2004 (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, fever)
    • No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit
    • PGA ≤33mm
    • Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5mg per day
    • Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
  • Change from Baseline in SLEDAI-2K at Week 48 [ Time Frame: From Baseline (Day 1) to Week 48 ]
    The SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K; 30 days) measures disease activity. It is a global index and includes 24 clinical symptoms and laboratory variables that are weighted by the type of manifestation, but not by severity or dynamic of the individual item. The total score falls between 0 and 105, with higher scores representing increased disease activity.
  • Achievement of BILAG improvement without worsening at Week 48 [ Time Frame: Week 48 ]
    The British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) grading is anchored in the physician's intention to treat. Disease activity is graded separately for 9 body systems (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, hematology) to 5 different grades (A to E) as follows: A ("Active") = Severely active disease B ("Beware") = Moderately active disease C ("Contentment") = Mild stable disease D ("Discount") = Inactive now but previously active E ("Excluded") = Never affected
  • Change from Baseline in PGA at Week 48 [ Time Frame: From Baseline (Day 1) to Week 48 ]
    Physician's Global Assessment of Disease (PGA) The Investigator will rate the overall status of the study participant in response to the following statement: "Please mark a vertical line on the scale below to assess the overall status of the study participant's Systemic Lupus Erythematosus signs and symptoms and the functional capacity of the study participant. The very far left end is 'very good, asymptomatic and no limitation of normal activities'; the very far right end indicates 'severe disease' . This refers to the most severe possible disease, and does not reflect the most severe ever seen in a particular patient, but the most severe disease ever seen in all SLE patients." When scoring the PGA, the assessor should always look back at the score from the previous visit.
  • Achievement of SRI4 response at Week 48 [ Time Frame: Week 48 ]
    The Systemic Lupus Erythematosus Responder Index (SRI)-4 define responders as (ie, all criteria must be met):
    • Reduction in SLEDAI-2K score of ≥4
    • No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline
    • No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline
    • No worsening in the PGA compared to study entry defined as ≤10mm increase on a 100mm visual analog scale
  • Achievement of prevention of moderate/severe BILAG flares through Week 48 [ Time Frame: Week 48 ]
    BILAG severe flare is defined as a new BILAG 2004 Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG- 2004 index (Yee et al, 2010)
  • Time to severe BILAG Flare through Week 48 [ Time Frame: During Treatment Period up to Week 48 ]
    BILAG severe flare is defined as a new BILAG 2004 Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
  • Time to moderate/severe BILAG flare through Week 48 [ Time Frame: During Treatment Period up to Week 48 ]
    BILAG severe flare is defined as a new BILAG 2004 Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010). BILAG moderate flare is defined as 2 or more BILAG 2004 Grade Bs due to individual items that are new or worse since previous visit and are qualifying for the Grade B in any system (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade B will be according to the supplementary information for the numerical scoring of the BILAG- 2004 index (Yee et al, 2010)
  • Percentage of participants with treatment-emergent adverse events (TEAEs) during the study [ Time Frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54) ]
    Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.
  • Percentage of participants with serious treatment-emergent adverse events during the study [ Time Frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54) ]
    A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose:
    • Results in death
    • Is life-threatening
    • Requires in patient hospitalisation or prolongation of existing hospitalisation
    • Is a congenital anomaly or birth defect
    • Is an infection that requires treatment with parenteral antibiotics
    • Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
  • Percentage of participants with treatment-emergent adverse events of special interest during the study [ Time Frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54) ]
    An adverse event of special interest is any AE that a regulatory authority has mandated be reported on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound.
  • Percentage of participants with treatment-emergent adverse events of special monitoring during the study [ Time Frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 54) ]
    An adverse event of special monitoring is a product-specific AEs, adverse reactions, or safety topics considered as requiring special monitoring by UCB.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Official Title  ICMJE A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
Brief Summary The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Systemic Lupus Erythematosus
Intervention  ICMJE
  • Drug: DZP
    Subjects will receive dapirolizumab pegol at prespecified time-points.
    Other Name: CDP7657
  • Other: Placebo
    Subjects will receive placebo at prespecified time-points.
    Other Name: PBO
Study Arms  ICMJE
  • Experimental: Dapirolizumab pegol
    Subjects will receive dapriolizumab pegol througout the Treatment Period.
    Intervention: Drug: DZP
  • Placebo Comparator: Placebo
    Subjects will receive placebo througout the Treatment Period.
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 2, 2020)
450
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE April 2023
Estimated Primary Completion Date February 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Study participant must be ≥16 years of age
  • Study participants who have moderate to severe disease activity due to either persisting active SLE or due to an acute worsening of SLE in the scope of frequent flaring/relapsing-remitting systemic lupus erythematosus (SLE) despite stable standard of care (SOC) medication defined as:

    1. Diagnosed with SLE at least 24 weeks before the Screening Visit (Visit 1) study entry by a qualified physician
    2. Classified by 2019 SLE European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE
    3. With serological evidence for SLE at Screening as demonstrated by at least 1 of the following:

    i) Evidence for anti-dsDNA (in central laboratory at Screening) ii) Either complement C3 < lower limit of normal (LLN) OR complement C4 <LLN OR elevated erythrocyte-bound complement C4d (where available) as measured by central laboratory iii) Antinuclear antibodies with a titer of at least 1:80 confirmed by central laboratory in combination with evidence of at least 1 of the following SLE typical autoantibodies:

    1. Anti-Smith (anti-Sm) antibodies (central laboratory)
    2. Anti-Sjögren's syndrome antibody A (Anti-SSA) (Ro)/Anti-Sjögren's syndrome antibody B (anti-SSB) (La) autoantibodies (central laboratory)
    3. Historic evidence for anti-dsDNA antibodies d. Moderately to severely active defined as
  • British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade B in ≥2 organ systems and/or a BILAG 2004 Grade A in ≥1 organ systems at Screening and Baseline Visit AND
  • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≥6 at Screening Visit AND
  • SLEDAI-2K without labs ≥4 at Baseline Visit e. Receiving the following SOC medication at stable dose:

    • Antimalarial treatment in combination with corticosteroids and/or immunosuppressants or as stand-alone treatment if justified OR Treatment with corticosteroids and/or immunosuppressants if anti-malarial treatment is not possible

Exclusion Criteria:- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life threatening condition

  • Study participant has a history of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies
  • Study participant has a history of malignancy, except the following treated cancers: cervical carcinoma in situ, basal cell carcinoma, or dermatological squamous cell carcinoma
  • Study participant has an increased risk for thromboembolic events due to an ongoing heart disease or due to a medical device, including but not limited to vascular graft, valvular heart disease, atrial fibrillation, or a heart rhythm disorder
  • Study participant has evidence of human immunodeficiency virus (HIV) infection, agammaglobulinemias, T-cell deficiencies, or human T-cell lymphotropic virus-1 infection
  • Study participant had a reactivated latent or opportunistic infection within 12 weeks prior to the first study medication infusion (Visit 2), or is currently receiving suppressive therapy for an opportunistic infection
  • Study participants who have received live/live attenuated vaccines within 6 weeks prior to the first study medication infusion
  • Study participant has clinically significant active or latent infection
  • Study participant has a mixed connective tissue disease, scleroderma, and/or overlap syndrome of these diseases with SLE
  • Study participant takes any protocol defined prohibited concomitant medication
  • Study participant has previously been randomized within this study or participant has previously been assigned to treatment with dapirolizumab pegol (DZP) in a study evaluating DZP
  • Study participant has participated in another study of an IMP within the previous 12 weeks or 5 half-lives of the investigational medicinal product (IMP) whatever is longer or is currently participating in another study of an IMP
  • Study participant has chronic kidney failure stage 4, manifested by estimated glomerular filtration rate <30mL/min/1.73m2, or serum creatinine >2.5 mg/dL, or participant has proteinuria >3 g/day, or protein: creatinine ratio >340 mg/mmol at the Screening Visit
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 16 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: UCB Cares +1844599 ext 2273 UCBCares@ucb.com
Listed Location Countries  ICMJE Argentina,   Australia,   Austria,   Belgium,   Bulgaria,   Canada,   Chile,   Colombia,   Czechia,   France,   Germany,   Greece,   Hungary,   Italy,   Korea, Republic of,   Peru,   Philippines,   Poland,   Portugal,   Serbia,   Spain,   Taiwan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04294667
Other Study ID Numbers  ICMJE SL0043
2019-003406-27 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Clinical Study Report (CSR)
Time Frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access Criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
URL: http://clinicalstudydatarequest.com
Responsible Party UCB Pharma ( UCB Biopharma SRL )
Study Sponsor  ICMJE UCB Biopharma SRL
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: UCB Cares 001 844 599 2273 (UCB)
PRS Account UCB Pharma
Verification Date July 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP